Curvebeam Ai Ltd. · ASX:CVB
Curvebeam Ai — Investor Presentation (April 2024)
17 slides from Curvebeam Ai's investor presentation, Apr 30, 2024
Slide 1: Quarterly 4C Conference Call
QUARTERLY 4C CONFERENCE CALL April 30 2024
Slide 2: Disclaimer
DISCLAIMER Introduction THIS DOCUMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, Forward looking statements DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY The information given in this presentation is given for illustrative purposes only
Slide 3: 4C Summary of Key Activities
4C SUMMARY OF KEY ACTIVITIES • During Q3 FY24, CurveBeam AI received purchase orders (POs) for 6 devices for the quarter: • 3 HiRiseTM POs from European customers • 2 LineUP® POs in the US • 1 PedCat® PO in the US • This is a significant increase over the prior corresponding period of 1 HiRiseTM. TM
Slide 4: 4C Summary of Key Activities
4C SUMMARY OF KEY ACTIVITIES • The Company continues to advance the development of an enhanced HiRise™ within its targeted timeline and still expects launch in Q1 FY25. • The timeline for the enhanced HiRise™ remains: • Q4 FY24: Continued cadaver validation, and orthopaedic surgeon validation of kne
Slide 5: Enhanced HiRise Project
ENHANCED HIRISE™ PROJECT • CurveBeam AI is developing enhancements to the HiRise™ platform. • Enables WBCT scans of larger patient hip & knee, to meet key landmarks and specifications required for robotic surgical system planning. • Company expects acceptance of HiRiseTM datasets for knee replacemen
Slide 6: BMD HiRise Module Progress
BMD HIRISE™ MODULE PROGRESS • BMD module is targeting a key annuity stream for sales & profit growth off knee & hip scans. HiRise™ a change • In the US, there are approx.1.6 million hip and knee total joint replacements, agent versus approx. 350,000 ankle-related procedures per annum. • FDA submissi
Slide 7: In Closing
IN CLOSING • HiRise™ placements • Enhanced HiRise program progressing on time. • Q4 Company expects to have customers using the enhanced HiRise on patients for robotic datasets. • Expect that initial placements should demonstrate utility of HiRise™ for custom knee procedures, which will support furt
Slide 8: Investment Highlights
CurveBeam AI’s HiRise Weight bearing CT INVESTMENT HIGHLIGHTS Combining Weight Bearing CT (WBCT) imaging equipment with AI solutions to target faster, First to market KOL & Clinical Validation Natural bilateral WBCT & Non WBCT, point of Key KOL sites as users – Mayo, Duke, HSS more efficient point o
Slide 9: Weight Bearing Cone Beam CT for Total Alignment
WEIGHT BEARING CONE BEAM CT FOR TOTAL ALIGNMENT ü Quicker and easier to scan than traditional CT and MRI, ü Radiation dose lower than traditional CT – up to 66% less with faster image acquisition time than traditional CT ü High resolution and 3D visualisation enables ü Smaller and lower-cost hardwar
Slide 10: Land & Expand Commercialisation Strategy
LAND & EXPAND COMMERCIALISATION STRATEGY • CurveBeam AI utilises a NORTH AMERICA Operations HQ combination of specialist 5 Sales reps, 2 Marketing EUROPE distributors and direct salesforce Strategic partners 8 Distributors ASIA to drive global sales 132 Placements 4 Sales reps 4 Distributors 35 Plac
Slide 11: Large Market Opportunity and Ongoing Adoption by Leading Customers
LARGE MARKET OPPORTUNITY AND ONGOING ADOPTION BY LEADING CUSTOMERS CurveBeam AI’s target Potential US WBCT Potential US customer groups Installation Sites1 Addressable Market2 Select CurveBeam AI customers • Mayo Clinics (all 3 major locations) Orthopaedic Surgeons & Group Practices Surgeon group pr
Slide 12: Investment Proposition for Surgeons
INVESTMENT PROPOSITION FOR SURGEONS Existing reimbursement codes target an attractive financial model for HiRise users • The average Medicare reimbursement rate for scans of the lower extremity CPT code relevant to the HiRise™, pedCAT™ and LineUP™ was US$138.77 per scan in 2022. Atlantic Orthopedic
Slide 13: Stryker Foot & Ankle Co-Marketing & Distribution US Partnership
STRYKER FOOT & ANKLE CO-MARKETING & DISTRIBUTION US PARTNERSHIP Stryker is a market leader in orthopaedics with US$18b in sales in FY22. STRYKER CORPORATION (NYSE:SYK) BACKGROUND • Leading multinational medical technology company - Orthopaedics & Spine contributes circa 55% of Stryker’s US$18b sales
Slide 14: Bone Health: Current Diagnostic (DEXA) Misses Majority of Fragility Fractures
BONE HEALTH: CURRENT BONE HEALTH DIAGNOSTIC (DEXA) MISSES THE MAJORITY OF FRAGILITY FRACTURES Bone fragility is caused by loss of bone microstructure, BONE FRAGILITY = BONE MICROSTRUCTURE BMD measures only bone density & not microstructure BMD is measuring bone density not bone microstructure BONE M
Slide 15: BMD and OssView Overview
S TA G E 1 – S E C O N D F X B U S I N E S S M O D E L An over 60 yr old fracture patient suspected of fragility fracture goes to FLS – non-osteoporosis – Impact or Fragility Fx? BMD AND OSSVIEW OVERVIEW AWS CurveBeam AI’s proprietary SaaS solutions leverage CT scans generated from its HiRise device
Slide 16: AI Modules Also Target Value Add Subscriptions on HiRise Install Base
AI MODULES ALSO TARGET VALUE ADD SUBSCRIPTIONS ON HIRISE INSTALL BASE CubeVue AutoMetrics aims to reduce 16 hours of CT dataset preparation prior to pre-surgical planning to a scan available in 15 minutes "To minimize future predicted costs, morbidity, THE PROBLEM THE SOLUTION & mortality from incre
Slide 17: Investment Summary
INVESTMENT SUMMARY CurveBeam AI produces and sells market leading weight bearing CT scanners. The Company has established key recognised clinical customers and a leading vendor partner. Regulatory First to market, FDA cleared, TGA and CE Marked Point of Care Weight Bearing and high resolution Cone C